Schwartz K A, Gauger J A, Davis J M
Department of Medicine, Michigan State University, East Lansing 48824.
Am J Hematol. 1990 Mar;33(3):167-76. doi: 10.1002/ajh.2830330304.
We report the development of a radiometric assay for platelet-bound IgG that is both sensitive and quantitative. The assay utilized 96-well millititer plates incorporating a 0.2 microns filter membrane in the bottom. A 125I-labeled monoclonal antihuman IgG, as a secondary antibody, detected the platelet-bound human IgG. Since 5 x 10(6) platelets were used for each assay, tests for platelet-bound IgG can be performed on persons with severe thrombocytopenia. For the detection of circulating antiplatelet alloantibodies, as little as 10 microliters of platelet-free plasma per assay is required. Antiplatelet IgG was quantitated by using anti-PIA1 antibody that was purified with affinity and elution and DEAE chromatography. This purified antiplatelet antibody was labeled with 125I and was used to determine the binding ratio of secondary antibody to primary antibody. Under our standard conditions, this ratio was found to be stable at approximately 0.35 over the sensitivity range of the assay. The assay can detect approximately 200 molecules of human IgG per platelet (0.1 ng of secondary antibody bound per 5 x 10(6) platelets). It has a linear range from 0 to 7,000 molecules per platelet. Quantitation of anti-PIA1 binding for platelets stored for up to 6 months under refrigeration showed no change in number of PIA1 binding sites. Clinical studies showed that 18 of 19 ITP patients had an increased number of IgG molecules per platelet as did patients with malignancy and drug-induced immune thrombocytopenia. Patients who had received multiple platelet transfusions had antiplatelet antibody in their plasma. Normal amounts of PAIgG were observed in platelets and plasma of patients with nonimmune thrombocytopenia. The advantages of this method are that it is: 1) a more precise quantitation of PAIgG via direct measurement of binding ratio with PIA1 antibody; 2) performed with small amounts of platelets and plasma; 3) both sensitive and specific; and 4) reliably reproducible with both fresh and stored platelets.
我们报告了一种用于检测血小板结合IgG的放射免疫测定法的开发,该方法既灵敏又可定量。该测定法使用底部带有0.2微米滤膜的96孔微量滴定板。用125I标记的单克隆抗人IgG作为二抗,检测血小板结合的人IgG。由于每次测定使用5×10⁶个血小板,因此可以对严重血小板减少症患者进行血小板结合IgG检测。对于循环抗血小板同种抗体的检测,每次测定仅需10微升无血小板血浆。通过使用经亲和、洗脱和DEAE色谱法纯化的抗PIA1抗体对抗血小板IgG进行定量。这种纯化的抗血小板抗体用125I标记,并用于确定二抗与一抗的结合率。在我们的标准条件下,该比率在测定的灵敏度范围内约为0.35时稳定。该测定法可检测每个血小板约200个人IgG分子(每5×10⁶个血小板结合0.1纳克二抗)。其线性范围为每个血小板0至7000个分子。对在冷藏条件下储存长达6个月的血小板的抗PIA1结合进行定量分析,结果显示PIA1结合位点数量没有变化。临床研究表明,19例特发性血小板减少性紫癜(ITP)患者中有18例每个血小板的IgG分子数量增加,恶性肿瘤和药物性免疫性血小板减少症患者也是如此。接受多次血小板输注的患者血浆中有抗血小板抗体。在非免疫性血小板减少症患者的血小板和血浆中观察到正常量的血小板相关IgG(PAIgG)。该方法的优点在于:1)通过直接测量与PIA1抗体的结合率对PAIgG进行更精确的定量;2)使用少量血小板和血浆即可进行;3)既灵敏又特异;4)对新鲜血小板和储存血小板均能可靠地重复检测。